Gene-Editing Clinical Trial Updates - What's...
CMN Clinical
Apr. 10, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Caribou Biosciences
Main focus: Next generation allogeneic CAR-T and CAR-natural killer (NK) cell therapies
Company stage: Clinical
Diseases: Non-hodgkins lymphoma (NHL), multiple myeloma (MM), acute myeloid leukaemia (AML)
Genome editing tool: CRISPR-Cas9, CRISPR-Cas12a
Funding stage: Public (NASDAQ:CRBU)
Location: Berkeley, CA, USA
Website: https://www.cariboubio.com/
Pipeline: https://www.cariboubio.com/pipeline/
Partners: Abbvie, ProMab Biotechnologies, MaxCyte
Caribou Biosciences develops novel allogeneic CAR-T and CAR-NK cell therapies. It uses CRISPR-Cas9 and CRISPR-Cas12a to knock out multiple genes, such as TRAC (endogenous T cell receptor) in healthy donor-derived T cells, and PD-1 and B2M to armor the cells. The company is testing its CB010 programme, directed towards CD19, in early clinical trials. Caribou is also developing multiple pre-clinical assets. The company is co-founded by Nobel prize winner, Jennifer Doudna.
Tags
Related News and Updates
Clinical Trials
Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06128044)
Sponsors:
Caribou Biosciences, Inc.
Sponsors:
Caribou Biosciences, Inc.
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, B-NHL, (NCT04637763)
Sponsors:
Caribou Biosciences, Inc.
Sponsors:
Caribou Biosciences, Inc.
IND Enabling
Phase I
Phase II
Phase III
